{"ticker": {"uuid": "3b4f4918-a699-45c9-9d5f-aada95260928", "symbol": "MSB", "name": "Mesoblast Limited", "exchange": "ASX", "country": "AU", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Mesoblast (ASX:MSB) Shares Give Back Ground After a Sharp Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOUEtFam9WaXpBY1BqZjMyQ1M4WVVReHAtQnpuTGJLUTFJbHUzTThnOG5IUmpuRGtPMWliR25iOWtjQTczWG5KdktzUkdER2VfN0xVX1lZR01NTWdiSWhqQ09PaXc5UU1xTHhObzA3dU5HLXROWHhOejFNUENMRkw1MmFic284cjlSUG1RRlpnOWl0bDF0NmRvcUtTR3M3MW9x?oc=5", "source_name": "Kalkine", "published_at": "2026-07-17T04:36:00+00:00", "published_display": "17 Jul 2026 04:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Triggered Today's Move in the Mesoblast (ASX:MSB) Share Price?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQckVoeE8ydXhldzRKOThQWm84UEZ1THVEbnZsZC02X3didXNYYzVzN0NmcWQ4LWxnaHd2UnBHMjJyTUF4SWpzNC11WDhoUnVCR0ZjN08tSFRyX1VvVC1RUWt0OVpqcUtXbVJ6TXJPekMzVnNWb0QzMUVnOUprdXZCQlR2V0piTVV6VmNUMVNRY0MwOVAwX000Q2duLUFsdVNlZ2RZ?oc=5", "source_name": "Kalkine", "published_at": "2026-07-17T02:06:00+00:00", "published_display": "17 Jul 2026 02:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX: MSB) Leaps 4.83% To AUD 2.72 As Biotech Buyers Return", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOV1F2RklQOUJiNjNkSlR3TUZQcm9taTVZaVRGY0RfX3J5NWdIcEduU1ZodF9sTGFQcWhERzU4UUpOQjZCQjVoS1NIR0NNRnA0alZsbE5ZelV1X2JLZFlLcUVLLWp2bmZvcXptM0o2b3FNZlhQcndOQm9vSzd2bmZSYmZ1TWhvcHlCX3R0TVhBel8yaWNHR0poOTdzb1dZU0dFVHBSNg?oc=5", "source_name": "Kalkine", "published_at": "2026-07-16T10:09:00+00:00", "published_display": "16 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) shares Jump :Is the Market Betting Big on Ryoncil's Next Chapter?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOYmtoZUkyN0RfRXZBVXNXZXg3OEloWXkzMHEtZlJ1d3pqRE9ycG1IcmRtMG01VVlZS1NMcGhtbnJhYUNRaDlCZDc1OVpuSW1oQmRwOW9vMDU3WGtJel9xb0taNzIyang0TUVGNmxiX3gta1UwNjAwdW1IZ3JwZGRHWjFLaHJVdjFydF9uOVFJdzZOQWpsa0VrcC1fVmpUOHFiWS05Y1lrUF9IOG9mT2lSRVNDdXFfWkR0V0E?oc=5", "source_name": "Kalkine", "published_at": "2026-07-16T07:25:00+00:00", "published_display": "16 Jul 2026 07:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Limited (MESO) sees 278,571 director options lapse in July", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPTndRbWtxMXJfUVhwNHJFYlE0OU9uYmt0ME1VSmtBbEZ0MTFaVlQ4X05hWWFmbGtMWVlOb0g1UTFJMTZaOFk4Sm1YUVFOVG9nYlhQd2V5ZnhKOHhtbXdIa0xlaUZzSHJqMU9iNmRkTk9zdEVNX09BVG15N0lOUE1mcDlzRUtQYTJlOVJtejFvbHppRk9keDNPeElCYUpfRTBodGFTa3loWld2NjBsX2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T10:06:03+00:00", "published_display": "15 Jul 2026 10:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Mesoblast (ASX:MSB) Leading the Next Wave of ASX Mid-Cap Healthcare?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQSjFmdnFxSEw2X1ctek9VRC0yTVhTd2p5X2RQd0NXTVpwbVItY2NsaWdnWDkxWUxsSWw0ZV95dXpjQS1WTHlXSkotUzc1Y2Zkb2k0QzktcHdYR0V6TWxHc3VKaWxfX0hrbXRNbnk5REUtRTl3N1ZoYTBheko2R0U5NU5hX1NBWWZIWnBBaTBoRjVHdFV1MlFjQTBBdmQyQzdOYlZNOFltd0dqYnd2QW1vdkFFYw?oc=5", "source_name": "Kalkine Media", "published_at": "2026-07-15T05:39:00+00:00", "published_display": "15 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Climbs as Global Biotech Dealmaking Heats Up", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQV3pqWUhUUV9kYXl6YVVCUC0zNzRZYWpLZEJObFhmanV1T2RldkxOQWtsaG1kS2VRdTVuSmliYUhxZldOQWNsWXA2a3hsa2ItY0FYMFlqcnUzRmxlSEw5Y3ExNktCQVpkV0xqMFB2TkxqcFRkb0U3YTlRM3VGX3QwNXMxZHRpSk45NFBiRjhwYThNeTVySmViS1RTWVp1YUFBN1VrckZR?oc=5", "source_name": "Kalkine Media", "published_at": "2026-07-14T12:24:00+00:00", "published_display": "14 Jul 2026 12:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Issues 2.25 Million Ordinary Shares Under Employee Share Option Plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPTXdhSEVuWVNqN3l4WDlqWUMtSFo5UV9paktDamFJazdsZEZpU3BESnBmdXB5MzJKSk94NGREX3VnWmItVEFDbE1PX1IxZEdlSGRrUjA5Z25rV0szSVpXVFlVQk1MVHNmNkdfcnFtZ2E1LUVoU2ZfNG1KQ2RfbGt1UjVtNzE3NHN0TjBuU1V5WkVvaUVRdG9UN2xWcmFsdi01VjJMcGtIcWZabG9kdzlyQ29QZkQxMjFTNFJz?oc=5", "source_name": "Kalkine", "published_at": "2026-07-14T09:54:12+00:00", "published_display": "14 Jul 2026 09:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Shares Rise: A Closer Look at the Cell Therapy Company's Market Position", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQUV83aDhKMXZUWFlVQkVNSDlNeURydkdxS1A0N1g4VVZuczNQXzBST3FIcnE1ellvWXNmYkhjeHBQaDZwLVFPMi1tbVdNWjVKbmxSZ0UtLXZxY0pWdkE2NjRDMzU2OEtSelhnMjlsRmJiVXR3RlNTemk4YmFtVFhjeFBuYlp5OUdvZnpfdkN0aklsN1hKekFKcEY2VFJVZG1Ec0hGczgwXzZPYmNYODVYWFowNUQ2TmRGR19DUk5Pa2hEV1pp?oc=5", "source_name": "Kalkine", "published_at": "2026-07-13T07:27:00+00:00", "published_display": "13 Jul 2026 07:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Shares Surge: Why This ASX Biotechnology Stock Is Back in Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOYkxUQVpxMzF1dFczc3RwX1dNal9FS1NqT1lzYWk2dFY3X0M2OTFPVHJjWlN4Slc5V0hoTTNEYW45dEZnTHdwU0NudXNSZERGMmRjMEVyb3h3NVgweHVyd2FRWmc3Mms5dC1YcFRBN3p6T1NDVk1vSjNQVEJGVnY0dGZ2aVVuOVE4em9VX3BIaGVBZUhpU3JwaGVlNm1VSmNNbWU4TmhlTGJVSlhVQW1wUm5wVEFSUE5CUUE?oc=5", "source_name": "Kalkine", "published_at": "2026-07-13T07:13:00+00:00", "published_display": "13 Jul 2026 07:13", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Mesoblast shares could double in value", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQWk9heENsRmZ1MjRpbTJMTmExcGlqS1FidEhwX1NkZ2hUcldwZ1BuTjZoNTZQWmdxTEFsRjI1QXM1ZEgyZUxuWUR5Mk5kdDVmVTNhMDNHTExxVHhXWXZrLUVOR2pJOGg3Ri1IUDdMVTBDRXdlcWd2eWZ6TmlIZldQbGFXTzQ?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2026-07-12T21:17:00+00:00", "published_display": "12 Jul 2026 21:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Posts Record Quarterly Revenue", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQYlZ4dGc3OWl6X2xmVlZwSV96NEV5bWhzY2o0bWRScURiOUtEZ0FQWmttc0ZCekNjYVNaTlVubG43RTBMc0I2X0NORV9EZVp4U3BXY18zZnIweFZXdkI0dnJoQ1h1SkdEX1FkcEJXNjBnelRlYU9ENUhJQ213U3hmUEZwV3dzc2drWW5WV2ZrZw?oc=5", "source_name": "Kalkine", "published_at": "2026-07-10T02:21:00+00:00", "published_display": "10 Jul 2026 02:21", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mesoblast (ASX:MSB) Undervalued Following FDA Progress For Rexlemestrocel L?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOcVVjOWUydFpWNFphRXA4ZmdmNkxSVWlsd2xsTDNTZ3BvbVkxbDFaUHFzdThhZURoS3I3bzQ4TDRzR29TSDFSbnotaXlEenQxeU9IWkxpcWlVbWw4U3Z1SXhxRmJIU0dITlh6bk82MlRMVVZZUFVuMDVCUk9ZdkZPU1dfTVI4SWh0R1dSZ29HV3ZNaHBMY29ZNTZROXRjXzNhaENqci1rbHJMMjdTbGhoZTJvb0NDMkE2RHplLV85Z2dCRkxSQzhMYUhnYUpyOEd6WlJFZXhSZEduaGhTVk1Z0gHkAUFVX3lxTE1jTDhSYTNJd0d1YVRWNjhZQlMtNHpyWXB1VE44a1JiSm5QRFFVYTlKZi1BaDRZc21vYmhhYm8zMUFaU3BtOGlsbzNqcElSZVczaERVdG9vQnRiazlSSS1CSWctSlZMbVlwNFRYTXNXSnJ2bDBoLVRLcG9wdXBZVXhVYUtkZzhLbFhWTWJ4N0tFRFZnWXVHRkQ0Rm0wUEVoQ25yX1FhNGE1NlNxTzZVR0N0aVBkV2FpeHYwRHcwLXVNNy0xMTJXN3hnRllRSHpidmcwMWlkMFdpMXZoRXRXRVhraGViYw?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Climbs as Biotech Bulls Return to the ASX Healthcare Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxONWY3YUMza3d0Q2ZpYmtsQ1BxUTI1cjBlOGVpcUEwNVJ0dDEzdmVldG10NEpFdzJMYl9odk9SSmZUTEVQN3dMT25KbHJXTEU3VnMzcjRaeTBIeFhHZkR4VXlpamltaVY1bVFZeHA3WmNOZTJFcW93WnhUVnltWTVLVG1vLXNpSmRVVTF5Z1dDUWUtMVJrTGpjdkJlY3A5THlPejlmdldoaW1VbWpOME40TzZJYjI?oc=5", "source_name": "Kalkine", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Why This Biotech Refuses To Leave Spotlight", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNWXR3ZWQ5c3liZUxKTUN2Rm4tdTU4cUdTa0Y3SFh5aElfRC0tUlFGZlFNN2k3THF0cUx0ek5hZmJxOTNtM25uR2w4ZVpNRXNJVW9wbzhyQXpkU2xYME9VWHFSMkVMYjNKanQ4YVNzVFBld0UxS01SSnNCZmRSQlFPM3R2LU9iT3VVdFRQb3lBenZ6NnF5a3dsVHBibVFQaTA3?oc=5", "source_name": "Kalkine", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Is Driving Increased Trading Activity in Mesoblast (ASX:MSB) Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPQmZGT1pJU2ZHZWVfSGNJYjA1YjNKblQ5UW9xQ0NnYmxsRXowLV9uY0VGakNBQ3Q4QmhWZGR3WG1pcUduTGwyRDFxU0pUZjVBU1BBSzlaMmMzMFVuLUpqMXJMOUd6WnBJMWdBd0RQdXR3NWdrWWEybWhwY1dBSjZIVWhsN2h0eTU3Mm8xM05BSHg0ZVJ3RjV2b3RIMFhzQUItMDU0M2N4emxtaXlIb1E?oc=5", "source_name": "Kalkine", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Leads ASX Gainers Following High-Volume Trading Session", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNX3ZhY0lTOTRsaEtFY0FDNG9GYnhXNlJjMWJOUHBMNHZudVBRV3owU1ZsV1dsVXQybkVhdVlyd1I4OU40YS1jYjhFS25PTXVsc3BWSFpidXR5RTh3YzB4U2xlUk1xRUc1SzMtWlNQX29UWHpZeDUwbTE1dFV0U083QmxtTnlwb3lHZjRrZDZHRGlTa21iZlVTWVl0YnVDd2stanE1NUdwcjBiTXRCNUdsdQ?oc=5", "source_name": "Kalkine", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Advances CAR Cell Therapy Platform And Late Stage Pain Trial", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why are Mesoblast shares jumping 8% today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPNUVjUGh4TGx1THdnUVM3alBndGE2Vnl2UjJuSl9yZDVWMk9NdHk3R3VzYUVuLVZya0xsUGRFcmdQSXNRVzd4N3dvLUFxZ3hTMmkxeW0yM2ljN1NPWVBBNG5RcWFrRVZFMVFldWtrQ05aRkNoaWxZNHBRUy1KSlEwNzZR?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Limited: A Risk/Reward Story (NASDAQ:MESO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPODMzMzJ4eFRKc1czX25ERVVMVGs3SzZObUMxRU5rRVJvamp1YVFjVm9MSHNCdTRFRWo3aVA4ZzZCbXBCT2RrXzZTQmx0SXB4amVfSFNSaW1EWGZQcXhMOTlhcTczbXZRODBuLUdYNHFXWjlRQ1BMY05oUHh0UE9nWkp4SQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast says Ryoncil is nearing $100M as new trials move ahead", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQbzZoSFRVQXM3OHUyN2RqSHlMZUlFS2NWRDJ5R2hyT3JTUC1RaEVtVlAxVmprYS1qck5GUlBNWEZwLUNiVWNLT0NJVmFrc1NBOGNaanRSSzJLaWxCb2RvR3hwaTlRdDFKOVltRWE2QjFlbVlKb2hyRGxCTWdiMGw1ckNCRVgyb1B2RmtINlQtRVJJU3lJOWxPdEl5U294ai1xc0g1OWJPNU83azNLQW9PYTNKY0NuVU9HMDY4b19Ucw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mesoblast (ASX:MSB) Price Swings Creating A Possible Valuation Opportunity?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPdXRPZTRnbWRCZktta0g0YWdFVWhEa1pRaWNrcGduWnN6RDJVUUJrQWRTWW81RXFoc2k0MmhDeEl4MlpzTEhWcjEzcnh2QWNGdm9LWnVIcUJFZUhjTDM5dGtXTGlNR1JRdkVKcFhBdVd6NkZqTFpCa0dOdThtMzNxXzlwaDZWR0l1Z1ozMXBGblhaQ1EwUDN4NkpRdw?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mesoblast (ASX:MSB) Offering Value After Recent Share Price Declines?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast to spotlight multi-billion pipeline at April 8 R&D Day", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPeW1KNnFnV2EzV3RXZThjTGdyVkFMQVVnQzhOY3BRUnktRkR6VFpjY3ZiSUxnSmlnNE1YdVNJQTFCYno0RG9NY3ktMGVNMllEOUZsYXR1dXhHM1NheVZyVkhlYjRjLThGbENaOUxiaXoxVzZrUFJvMXNuQVBOSm11NkdMVk9zVjFRWnFTUUVXMDQwRzJLS2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast H1 2026 Loss Of US$94.4 Million Tests Bullish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Is Down 7.1% After Issuing First Ryoncil 2026 Revenue Guidance \u2013 Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE56ZjVJaVI3VG9rT1F0SmZvTzZvX2ZLTVpWOFJhN3BvbkVsZEsxNm1oa1lhSHZKWDFWU3kyWEthSzhkbE9UMmZoaGdoY0NkQXZ0WGNqQlNQT3RwYkVUVjJ6cTgtWGpNdHdhTEJOTjVWSVRmLXBQQXQ4OTF3?oc=5", "source_name": "Market source", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB): Reassessing Valuation After Recent Share Price Rebound and Long-Term Return Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQU0x3bkRVbmJpVndUQnFQRVhTWDhpR2czajF3amVFeWFxV0VNV0VmMi1JZURDMk5xY2k1QWRBbUdncHBiY3BBaFhyYmdZMkNMTzBHTExfa09CbGZCM3Bid090d3lXMF83alV6WWZBVEFGLXVJb1E1U3U5c2R6V2prMHRwVTlOaTZIaGlCbjF3?oc=5", "source_name": "Market source", "published_at": "2025-12-16T08:00:00+00:00", "published_display": "16 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Limited (ASX:MSB): Are Analysts Optimistic?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxOVFBYTUFDUjN2SnU1dFBpNTVfTnpCZDZ3Q0l6cjFoWXVkRDluMG92WnBQOVdBUWxnM09DeUhpaDE5QmktS25RdEtVLXdhLXh3OUt1VFZKdURUeldBSWswclRpX3hiNjRxZVlvVEhTbXF0eDJHMENSYncxbThkYThPM25MUzh4Q28?oc=5", "source_name": "Market source", "published_at": "2025-11-11T08:00:00+00:00", "published_display": "11 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB): Assessing Valuation Following Recent Share Price Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPalV4bkRja2tsMk5UWE9LTGdMZ2ZERTdGeEN1Q3poSVdqMU9oMU83WVIyQUlZRm85REEzblM2OGZXSFpLNUNLRWZnQkdnZ3NhZExHeWxkU2NmSi1tZGNoRXozMm85SVFadl9IR1ppMk1rMnRkeVJmYjY0NmxMZnZnY3RtZzV5bVZjWHRN?oc=5", "source_name": "Market source", "published_at": "2025-10-04T07:00:00+00:00", "published_display": "04 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Mesoblast (ASX:MSB) Shares Give Back Ground After a Sharp Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOUEtFam9WaXpBY1BqZjMyQ1M4WVVReHAtQnpuTGJLUTFJbHUzTThnOG5IUmpuRGtPMWliR25iOWtjQTczWG5KdktzUkdER2VfN0xVX1lZR01NTWdiSWhqQ09PaXc5UU1xTHhObzA3dU5HLXROWHhOejFNUENMRkw1MmFic284cjlSUG1RRlpnOWl0bDF0NmRvcUtTR3M3MW9x?oc=5", "source_name": "Kalkine", "published_at": "2026-07-17T04:36:00+00:00", "published_display": "17 Jul 2026 04:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Triggered Today's Move in the Mesoblast (ASX:MSB) Share Price?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQckVoeE8ydXhldzRKOThQWm84UEZ1THVEbnZsZC02X3didXNYYzVzN0NmcWQ4LWxnaHd2UnBHMjJyTUF4SWpzNC11WDhoUnVCR0ZjN08tSFRyX1VvVC1RUWt0OVpqcUtXbVJ6TXJPekMzVnNWb0QzMUVnOUprdXZCQlR2V0piTVV6VmNUMVNRY0MwOVAwX000Q2duLUFsdVNlZ2RZ?oc=5", "source_name": "Kalkine", "published_at": "2026-07-17T02:06:00+00:00", "published_display": "17 Jul 2026 02:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX: MSB) Leaps 4.83% To AUD 2.72 As Biotech Buyers Return", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOV1F2RklQOUJiNjNkSlR3TUZQcm9taTVZaVRGY0RfX3J5NWdIcEduU1ZodF9sTGFQcWhERzU4UUpOQjZCQjVoS1NIR0NNRnA0alZsbE5ZelV1X2JLZFlLcUVLLWp2bmZvcXptM0o2b3FNZlhQcndOQm9vSzd2bmZSYmZ1TWhvcHlCX3R0TVhBel8yaWNHR0poOTdzb1dZU0dFVHBSNg?oc=5", "source_name": "Kalkine", "published_at": "2026-07-16T10:09:00+00:00", "published_display": "16 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) shares Jump :Is the Market Betting Big on Ryoncil's Next Chapter?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOYmtoZUkyN0RfRXZBVXNXZXg3OEloWXkzMHEtZlJ1d3pqRE9ycG1IcmRtMG01VVlZS1NMcGhtbnJhYUNRaDlCZDc1OVpuSW1oQmRwOW9vMDU3WGtJel9xb0taNzIyang0TUVGNmxiX3gta1UwNjAwdW1IZ3JwZGRHWjFLaHJVdjFydF9uOVFJdzZOQWpsa0VrcC1fVmpUOHFiWS05Y1lrUF9IOG9mT2lSRVNDdXFfWkR0V0E?oc=5", "source_name": "Kalkine", "published_at": "2026-07-16T07:25:00+00:00", "published_display": "16 Jul 2026 07:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Limited (MESO) sees 278,571 director options lapse in July", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPTndRbWtxMXJfUVhwNHJFYlE0OU9uYmt0ME1VSmtBbEZ0MTFaVlQ4X05hWWFmbGtMWVlOb0g1UTFJMTZaOFk4Sm1YUVFOVG9nYlhQd2V5ZnhKOHhtbXdIa0xlaUZzSHJqMU9iNmRkTk9zdEVNX09BVG15N0lOUE1mcDlzRUtQYTJlOVJtejFvbHppRk9keDNPeElCYUpfRTBodGFTa3loWld2NjBsX2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T10:06:03+00:00", "published_display": "15 Jul 2026 10:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Mesoblast (ASX:MSB) Leading the Next Wave of ASX Mid-Cap Healthcare?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQSjFmdnFxSEw2X1ctek9VRC0yTVhTd2p5X2RQd0NXTVpwbVItY2NsaWdnWDkxWUxsSWw0ZV95dXpjQS1WTHlXSkotUzc1Y2Zkb2k0QzktcHdYR0V6TWxHc3VKaWxfX0hrbXRNbnk5REUtRTl3N1ZoYTBheko2R0U5NU5hX1NBWWZIWnBBaTBoRjVHdFV1MlFjQTBBdmQyQzdOYlZNOFltd0dqYnd2QW1vdkFFYw?oc=5", "source_name": "Kalkine Media", "published_at": "2026-07-15T05:39:00+00:00", "published_display": "15 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Climbs as Global Biotech Dealmaking Heats Up", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQV3pqWUhUUV9kYXl6YVVCUC0zNzRZYWpLZEJObFhmanV1T2RldkxOQWtsaG1kS2VRdTVuSmliYUhxZldOQWNsWXA2a3hsa2ItY0FYMFlqcnUzRmxlSEw5Y3ExNktCQVpkV0xqMFB2TkxqcFRkb0U3YTlRM3VGX3QwNXMxZHRpSk45NFBiRjhwYThNeTVySmViS1RTWVp1YUFBN1VrckZR?oc=5", "source_name": "Kalkine Media", "published_at": "2026-07-14T12:24:00+00:00", "published_display": "14 Jul 2026 12:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Issues 2.25 Million Ordinary Shares Under Employee Share Option Plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPTXdhSEVuWVNqN3l4WDlqWUMtSFo5UV9paktDamFJazdsZEZpU3BESnBmdXB5MzJKSk94NGREX3VnWmItVEFDbE1PX1IxZEdlSGRrUjA5Z25rV0szSVpXVFlVQk1MVHNmNkdfcnFtZ2E1LUVoU2ZfNG1KQ2RfbGt1UjVtNzE3NHN0TjBuU1V5WkVvaUVRdG9UN2xWcmFsdi01VjJMcGtIcWZabG9kdzlyQ29QZkQxMjFTNFJz?oc=5", "source_name": "Kalkine", "published_at": "2026-07-14T09:54:12+00:00", "published_display": "14 Jul 2026 09:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Shares Rise: A Closer Look at the Cell Therapy Company's Market Position", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQUV83aDhKMXZUWFlVQkVNSDlNeURydkdxS1A0N1g4VVZuczNQXzBST3FIcnE1ellvWXNmYkhjeHBQaDZwLVFPMi1tbVdNWjVKbmxSZ0UtLXZxY0pWdkE2NjRDMzU2OEtSelhnMjlsRmJiVXR3RlNTemk4YmFtVFhjeFBuYlp5OUdvZnpfdkN0aklsN1hKekFKcEY2VFJVZG1Ec0hGczgwXzZPYmNYODVYWFowNUQ2TmRGR19DUk5Pa2hEV1pp?oc=5", "source_name": "Kalkine", "published_at": "2026-07-13T07:27:00+00:00", "published_display": "13 Jul 2026 07:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Shares Surge: Why This ASX Biotechnology Stock Is Back in Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOYkxUQVpxMzF1dFczc3RwX1dNal9FS1NqT1lzYWk2dFY3X0M2OTFPVHJjWlN4Slc5V0hoTTNEYW45dEZnTHdwU0NudXNSZERGMmRjMEVyb3h3NVgweHVyd2FRWmc3Mms5dC1YcFRBN3p6T1NDVk1vSjNQVEJGVnY0dGZ2aVVuOVE4em9VX3BIaGVBZUhpU3JwaGVlNm1VSmNNbWU4TmhlTGJVSlhVQW1wUm5wVEFSUE5CUUE?oc=5", "source_name": "Kalkine", "published_at": "2026-07-13T07:13:00+00:00", "published_display": "13 Jul 2026 07:13", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Mesoblast shares could double in value", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQWk9heENsRmZ1MjRpbTJMTmExcGlqS1FidEhwX1NkZ2hUcldwZ1BuTjZoNTZQWmdxTEFsRjI1QXM1ZEgyZUxuWUR5Mk5kdDVmVTNhMDNHTExxVHhXWXZrLUVOR2pJOGg3Ri1IUDdMVTBDRXdlcWd2eWZ6TmlIZldQbGFXTzQ?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2026-07-12T21:17:00+00:00", "published_display": "12 Jul 2026 21:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Posts Record Quarterly Revenue", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQYlZ4dGc3OWl6X2xmVlZwSV96NEV5bWhzY2o0bWRScURiOUtEZ0FQWmttc0ZCekNjYVNaTlVubG43RTBMc0I2X0NORV9EZVp4U3BXY18zZnIweFZXdkI0dnJoQ1h1SkdEX1FkcEJXNjBnelRlYU9ENUhJQ213U3hmUEZwV3dzc2drWW5WV2ZrZw?oc=5", "source_name": "Kalkine", "published_at": "2026-07-10T02:21:00+00:00", "published_display": "10 Jul 2026 02:21", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mesoblast (ASX:MSB) Undervalued Following FDA Progress For Rexlemestrocel L?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Climbs as Biotech Bulls Return to the ASX Healthcare Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxONWY3YUMza3d0Q2ZpYmtsQ1BxUTI1cjBlOGVpcUEwNVJ0dDEzdmVldG10NEpFdzJMYl9odk9SSmZUTEVQN3dMT25KbHJXTEU3VnMzcjRaeTBIeFhHZkR4VXlpamltaVY1bVFZeHA3WmNOZTJFcW93WnhUVnltWTVLVG1vLXNpSmRVVTF5Z1dDUWUtMVJrTGpjdkJlY3A5THlPejlmdldoaW1VbWpOME40TzZJYjI?oc=5", "source_name": "Kalkine", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Why This Biotech Refuses To Leave Spotlight", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNWXR3ZWQ5c3liZUxKTUN2Rm4tdTU4cUdTa0Y3SFh5aElfRC0tUlFGZlFNN2k3THF0cUx0ek5hZmJxOTNtM25uR2w4ZVpNRXNJVW9wbzhyQXpkU2xYME9VWHFSMkVMYjNKanQ4YVNzVFBld0UxS01SSnNCZmRSQlFPM3R2LU9iT3VVdFRQb3lBenZ6NnF5a3dsVHBibVFQaTA3?oc=5", "source_name": "Kalkine", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Is Driving Increased Trading Activity in Mesoblast (ASX:MSB) Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPQmZGT1pJU2ZHZWVfSGNJYjA1YjNKblQ5UW9xQ0NnYmxsRXowLV9uY0VGakNBQ3Q4QmhWZGR3WG1pcUduTGwyRDFxU0pUZjVBU1BBSzlaMmMzMFVuLUpqMXJMOUd6WnBJMWdBd0RQdXR3NWdrWWEybWhwY1dBSjZIVWhsN2h0eTU3Mm8xM05BSHg0ZVJ3RjV2b3RIMFhzQUItMDU0M2N4emxtaXlIb1E?oc=5", "source_name": "Kalkine", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Leads ASX Gainers Following High-Volume Trading Session", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNX3ZhY0lTOTRsaEtFY0FDNG9GYnhXNlJjMWJOUHBMNHZudVBRV3owU1ZsV1dsVXQybkVhdVlyd1I4OU40YS1jYjhFS25PTXVsc3BWSFpidXR5RTh3YzB4U2xlUk1xRUc1SzMtWlNQX29UWHpZeDUwbTE1dFV0U083QmxtTnlwb3lHZjRrZDZHRGlTa21iZlVTWVl0YnVDd2stanE1NUdwcjBiTXRCNUdsdQ?oc=5", "source_name": "Kalkine", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Advances CAR Cell Therapy Platform And Late Stage Pain Trial", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why are Mesoblast shares jumping 8% today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPNUVjUGh4TGx1THdnUVM3alBndGE2Vnl2UjJuSl9yZDVWMk9NdHk3R3VzYUVuLVZya0xsUGRFcmdQSXNRVzd4N3dvLUFxZ3hTMmkxeW0yM2ljN1NPWVBBNG5RcWFrRVZFMVFldWtrQ05aRkNoaWxZNHBRUy1KSlEwNzZR?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Limited: A Risk/Reward Story (NASDAQ:MESO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPODMzMzJ4eFRKc1czX25ERVVMVGs3SzZObUMxRU5rRVJvamp1YVFjVm9MSHNCdTRFRWo3aVA4ZzZCbXBCT2RrXzZTQmx0SXB4amVfSFNSaW1EWGZQcXhMOTlhcTczbXZRODBuLUdYNHFXWjlRQ1BMY05oUHh0UE9nWkp4SQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast says Ryoncil is nearing $100M as new trials move ahead", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQbzZoSFRVQXM3OHUyN2RqSHlMZUlFS2NWRDJ5R2hyT3JTUC1RaEVtVlAxVmprYS1qck5GUlBNWEZwLUNiVWNLT0NJVmFrc1NBOGNaanRSSzJLaWxCb2RvR3hwaTlRdDFKOVltRWE2QjFlbVlKb2hyRGxCTWdiMGw1ckNCRVgyb1B2RmtINlQtRVJJU3lJOWxPdEl5U294ai1xc0g1OWJPNU83azNLQW9PYTNKY0NuVU9HMDY4b19Ucw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mesoblast (ASX:MSB) Price Swings Creating A Possible Valuation Opportunity?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPdXRPZTRnbWRCZktta0g0YWdFVWhEa1pRaWNrcGduWnN6RDJVUUJrQWRTWW81RXFoc2k0MmhDeEl4MlpzTEhWcjEzcnh2QWNGdm9LWnVIcUJFZUhjTDM5dGtXTGlNR1JRdkVKcFhBdVd6NkZqTFpCa0dOdThtMzNxXzlwaDZWR0l1Z1ozMXBGblhaQ1EwUDN4NkpRdw?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mesoblast (ASX:MSB) Offering Value After Recent Share Price Declines?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxQOU9GTWRIQmZGWld3MFQ3RnVZNTFYcjlXNGpPTzBYVHRldEtKSjVCWW8zLUNxVkppY05sZTI1ZGNYam5SVGVpLWc0YTJLWUdnTTF3VUNwckpFQm4wY3AzYktnZWZmQThxRzhLajVzalowMWV2a1M0ZFpZVXdDVU9LTkNfaV9WMGN6WUM2NUQtNHBMWk9NcGJPS09kQTlyd3Y0bVpieHU5OG1HLVRFa2ZMWVV1bXN1MUlKWVFPYjRFclYtMllLTTlLek5IZzZ6V2swUVZ4aVNYVU1yS0J4VFHSAeMBQVVfeXFMTzA1cHA4b2N4N1RWd2FSWjhJUHk4SGNBak1VRUxuVjd4SXlpSXByM0w3VV9QbWVSdnRIUXd0LThzOWtDYUhENFF4YTBIOEJsaUMtVHhqNHdLMWZDSVREVkFtVEdVR3dLbGRVSmtLZi1ETjVMOXVIS0g3UHRjYVpzbFhOX052QWN6QTR2Y3FuNzJmZDJzMUdLQnNPc25kZE1EaE1tUF9DSXk1dXJFYkprXzNSaktQUUViUlJ1TFZGcHBkWjFSd2c2UEtfdlE3bEJsaS1zUHNISTNPbjJ6eGJaVzlBZFU?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast to spotlight multi-billion pipeline at April 8 R&D Day", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPeW1KNnFnV2EzV3RXZThjTGdyVkFMQVVnQzhOY3BRUnktRkR6VFpjY3ZiSUxnSmlnNE1YdVNJQTFCYno0RG9NY3ktMGVNMllEOUZsYXR1dXhHM1NheVZyVkhlYjRjLThGbENaOUxiaXoxVzZrUFJvMXNuQVBOSm11NkdMVk9zVjFRWnFTUUVXMDQwRzJLS2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast H1 2026 Loss Of US$94.4 Million Tests Bullish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Is Down 7.1% After Issuing First Ryoncil 2026 Revenue Guidance \u2013 Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE56ZjVJaVI3VG9rT1F0SmZvTzZvX2ZLTVpWOFJhN3BvbkVsZEsxNm1oa1lhSHZKWDFWU3kyWEthSzhkbE9UMmZoaGdoY0NkQXZ0WGNqQlNQT3RwYkVUVjJ6cTgtWGpNdHdhTEJOTjVWSVRmLXBQQXQ4OTF3?oc=5", "source_name": "Market source", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB): Reassessing Valuation After Recent Share Price Rebound and Long-Term Return Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQU0x3bkRVbmJpVndUQnFQRVhTWDhpR2czajF3amVFeWFxV0VNV0VmMi1JZURDMk5xY2k1QWRBbUdncHBiY3BBaFhyYmdZMkNMTzBHTExfa09CbGZCM3Bid090d3lXMF83alV6WWZBVEFGLXVJb1E1U3U5c2R6V2prMHRwVTlOaTZIaGlCbjF3?oc=5", "source_name": "Market source", "published_at": "2025-12-16T08:00:00+00:00", "published_display": "16 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Limited (ASX:MSB): Are Analysts Optimistic?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxOVFBYTUFDUjN2SnU1dFBpNTVfTnpCZDZ3Q0l6cjFoWXVkRDluMG92WnBQOVdBUWxnM09DeUhpaDE5QmktS25RdEtVLXdhLXh3OUt1VFZKdURUeldBSWswclRpX3hiNjRxZVlvVEhTbXF0eDJHMENSYncxbThkYThPM25MUzh4Q28?oc=5", "source_name": "Market source", "published_at": "2025-11-11T08:00:00+00:00", "published_display": "11 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB): Assessing Valuation Following Recent Share Price Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPalV4bkRja2tsMk5UWE9LTGdMZ2ZERTdGeEN1Q3poSVdqMU9oMU83WVIyQUlZRm85REEzblM2OGZXSFpLNUNLRWZnQkdnZ3NhZExHeWxkU2NmSi1tZGNoRXozMm85SVFadl9IR1ppMk1rMnRkeVJmYjY0NmxMZnZnY3RtZzV5bVZjWHRN?oc=5", "source_name": "Market source", "published_at": "2025-10-04T07:00:00+00:00", "published_display": "04 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 86, "total_relevant": 29, "sentiment_summary": {"positive": 4, "negative": 2, "neutral": 23, "score": 51, "total": 29, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 93, "events": [{"event": "general", "label": "Market update", "weight": 15.2, "count": 27}, {"event": "earnings", "label": "Earnings", "weight": 1.1, "count": 2}], "positive_events": 4, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 2.24, "latest_week": "2026-07-10", "one_week_move": 8.7, "four_week_move": 14.9, "twelve_week_move": -0.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.351595, "market_dynamics_buy_signal": false, "relative_strength": -5.491924, "fair_value_gap": 42.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 54.0672, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+8.7% over one week, +14.9% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Kalkine", "count": 12}, {"label": "Market source", "count": 5}, {"label": "simplywall.st", "count": 4}, {"label": "Stock Titan", "count": 3}, {"label": "Kalkine Media", "count": 2}, {"label": "The Motley Fool Australia", "count": 2}, {"label": "Seeking Alpha", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 29}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Earnings", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "93/100 classification confidence."}, {"label": "Company focus", "value": "29", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+8.7% over one week, +14.9% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Mesoblast (ASX:MSB) Shares Give Back Ground After a Sharp Rally"}], "updated_at": "2026-07-17T04:59:30.774577+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}